PMID- 18671707
OWN - NLM
STAT- MEDLINE
DCOM- 20081216
LR  - 20201209
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 143
IP  - 1
DP  - 2008 Oct
TI  - Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the 
      management of patients with heparin-induced thrombocytopenia.
PG  - 92-9
LID - 10.1111/j.1365-2141.2008.07300.x [doi]
AB  - Rivaroxaban is an oral, direct activated Factor Xa (FXa) inhibitor in advanced 
      clinical development for the prevention and treatment of thromboembolic 
      disorders. Currently available anticoagulants include unfractionated heparin 
      (UFH) and low molecular weight heparins (LMWHs); however, their use can be 
      restricted by heparin-induced thrombocytopenia (HIT). HIT is usually caused by 
      the production of antibodies to a complex of heparin and platelet factor-4 (PF4). 
      This study was performed to evaluate, in vitro, the potential of rivaroxaban as 
      an anticoagulant for the management of patients with HIT. UFH, the LMWH 
      enoxaparin, fondaparinux and the direct thrombin inhibitor argatroban were tested 
      to enable comparative analyses. Rivaroxaban did not cause platelet activation or 
      aggregation in the presence of HIT antibodies, unlike UFH and enoxaparin, 
      suggesting that rivaroxaban does not cross-react with HIT antibodies. 
      Furthermore, rivaroxaban did not cause the release of PF4 from platelets and did 
      not interact with PF4, unlike UFH and enoxaparin. These findings suggest that 
      rivaroxaban may be a suitable anticoagulant for the management of patients with 
      HIT.
FAU - Walenga, Jeanine M
AU  - Walenga JM
AD  - Cardiovascular Institute, Loyola University Chicago, Maywood, IL 60153, USA.
FAU - Prechel, Margaret
AU  - Prechel M
FAU - Jeske, Walter P
AU  - Jeske WP
FAU - Hoppensteadt, Debra
AU  - Hoppensteadt D
FAU - Maddineni, Jyothi
AU  - Maddineni J
FAU - Iqbal, Omer
AU  - Iqbal O
FAU - Messmore, Harry L
AU  - Messmore HL
FAU - Bakhos, Mamdouh
AU  - Bakhos M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080730
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Anticoagulants)
RN  - 0 (Autoantibodies)
RN  - 0 (Enoxaparin)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Morpholines)
RN  - 0 (Pipecolic Acids)
RN  - 0 (Polysaccharides)
RN  - 0 (Sulfonamides)
RN  - 0 (Thiophenes)
RN  - 37270-94-3 (Platelet Factor 4)
RN  - 9000-94-6 (Antithrombin III)
RN  - 94ZLA3W45F (Arginine)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - IY90U61Z3S (argatroban)
RN  - J177FOW5JL (Fondaparinux)
SB  - IM
MH  - Analysis of Variance
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Antithrombin III/*therapeutic use
MH  - Arginine/analogs & derivatives
MH  - Autoantibodies/immunology
MH  - Enoxaparin/adverse effects
MH  - Flow Cytometry
MH  - Fondaparinux
MH  - Heparin, Low-Molecular-Weight/*adverse effects
MH  - Humans
MH  - Morpholines/*therapeutic use
MH  - Pipecolic Acids/adverse effects
MH  - Platelet Activation
MH  - Platelet Aggregation/drug effects
MH  - Platelet Factor 4/adverse effects
MH  - Polysaccharides/adverse effects
MH  - Rivaroxaban
MH  - Sulfonamides
MH  - Thiophenes/*therapeutic use
MH  - Thrombocytopenia/*chemically induced/*drug therapy/immunology
EDAT- 2008/08/02 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/08/02 09:00
PHST- 2008/08/02 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/08/02 09:00 [entrez]
AID - BJH7300 [pii]
AID - 10.1111/j.1365-2141.2008.07300.x [doi]
PST - ppublish
SO  - Br J Haematol. 2008 Oct;143(1):92-9. doi: 10.1111/j.1365-2141.2008.07300.x. Epub 
      2008 Jul 30.